Major growth drivers of the cancer biomarkers market are rising prevalence of cancer and rising demand for personalized medicine in cancer therapies. However, the high cost of various cancer diagnostic tests, need for high capital investments, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection are restricting the growth of this market.
Premium Insights > Cancer Biomarkers: Market Snapshot > APAC Cancer Biomarkers Market, By Profiling Technology and Application > Cancer Biomarkers Market Share, By Cancer Type, 2017 vs 2022 > Cancer Biomarkers Market Share, By Biomarker Type, 2015 to 2022 > Cancer Biomarkers Market, By Region
Based on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers). During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.
Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers). The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.
Opportunity: Personalized medicine
Over the years, the popularity of personalized medicine has increased, due to limitations of standard diagnosis and treatment. Different fields of medicine, from cancer to psychiatry, are heading towards tailored treatments for each patient on the basis of his/her biological and clinical characteristics. The use of biomarkers has played a very important role in certain aspects of personalized medicine. Also, the importance of biomarkers is increasing in the field of personalized medicine, with applications in diagnosis, prognosis, and selection of targeted therapies. In terms of calculating disease risk and response to therapy, the continuous development and identification of biomarkers specific to a disease and individual patients is vital for personalized medicine. Thus, the field of personalized medicine is expected to offer potential growth opportunities for players operating in the cancer biomarkers market.
Challenge: Proving clinical validity and utility of biomarker-based tests
Despite the advances in biomarkers in the last few years, the lack of clarity regarding several basic elements is restricting their full potential in human medicine. Limited acceptance of robust clinical biomarker tests is one of the major challenges in this regard. Human diseases are mostly complex in nature; several biomarkers are required to describe the imbalance in the metabolic equilibrium responsible for the disease and the effect of treatment. The biomarker validation process includes the evaluation of the assay or measurement of performance characteristics, such as sensitivity, specificity, and reproducibility
North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe. North America is the largest market for cancer biomarkers majorly due to government support (in the US and Canada) for the discovery and development of biomarkers, rising use of biomarkers in drug discovery and development by pharmaceutical companies, adoption of advanced omics technologies for biomarker discovery, and the increasing demand for personalized medicine in the region.
The major players operating in the cancer oncology biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).
Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: +1-888-600-6441 Email: firstname.lastname@example.org
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: